Cerebral Small Vessel Disease in subclinical and clinical stages, role of inflammation for risk prediction and potential treatment targets, and management strategies
Abstract
Stroke and dementia are the most common neurological disorders worldwide. Cerebrovascular disease, particularly cerebral small vessel disease (CSVD) is implicated in both, and the two main types of CSVD (hypertensive vasculopathy and cerebral amyloid angiopathy) account for the majority of cerebrovascular contributions to stroke and dementia. Current knowledge of CSVD may influence treatment decisions and preventive efforts. Although the causes of CSVD are not entirely elucidated, ongoing research of the pathophysiology of CSVD, such as the role of inflammation, is helping identify potential treatment targets, evaluate prediction models and develop preventive strategies. Given the detectability of CSVD in preclinical stages using brain MRI, a long window of opportunity is presented to implement existent preventive measures. This review considers CSVD including its subclinical manifestations detected using brain MRI, clinical manifestations, use of markers of CSVD as predictors of clinical outcomes such as dementia and stroke, and presents potential management strategies when seeing patients with cerebral small vessel disease to reduce its disease burden and clinical consequences. Clinical trials have evaluated some aspects of CSVD treatment and are beginning to recognize CSVD as endpoint in subclinical stages. Future studies will clarify if this approach is able to delay onset of dementia and prevent stroke occurrence, meanwhile implementation of existent recommendations for the prevention and treatment of stroke and dementia may reduce disability and clinical outcomes related to CSVD.
Keywords
Full Text:
Subscribers OnlyReferences
WHO Neurological Disorders: Public Health Challenges. (n.d.). 2016; Available from: http://www.who.int/mental_health/neurology/neurodiso/en/.
Writing Group, M., et al., Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation, 2016. 133(4): p. e38-360.
Arntz, R.M., et al., Accelerated development of cerebral small vessel disease in young stroke patients. Neurology, 2016. 87(12): p. 1212-9.
Madigan, J.B., D.M. Wilcock, and A.H. Hainsworth, Vascular Contributions to Cognitive Impairment and Dementia: Topical Review of Animal Models. Stroke, 2016. 47(7): p. 1953-9.
Jastrzebski, K., et al., Hemorrhagic stroke, cerebral amyloid angiopathy, Down syndrome and the Boston criteria. Neurol Neurochir Pol, 2015. 49(3): p. 193-6.
Petty, G.W., et al., Ischemic stroke subtypes : a population-based study of functional outcome, survival, and recurrence. Stroke, 2000. 31(5): p. 1062-8.
Kolominsky-Rabas, P.L., et al., Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke, 2001. 32(12): p. 2735-40.
Pantoni, L., Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol, 2010. 9(7): p. 689-701.
Furuta, A., et al., Medullary arteries in aging and dementia. Stroke, 1991. 22(4): p. 442-6.
Greenberg, S.M., et al., Microbleeds versus macrobleeds: evidence for distinct entities. Stroke, 2009. 40(7): p. 2382-6.
Imaoka, K., et al., Leukoencephalopathy with cerebral amyloid angiopathy: a semiquantitative and morphometric study. J Neurol, 1999. 246(8): p. 661-6.
Kimberly, W.T., et al., Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology, 2009. 72(14): p. 1230-5.
Viswanathan, A. and H. Chabriat, Cerebral microhemorrhage. Stroke, 2006. 37(2): p. 550-5.
Smith, E.E. and F. Eichler, Cerebral amyloid angiopathy and lobar intracerebral hemorrhage. Arch Neurol, 2006. 63(1): p. 148-51.
Haglund, M., M. Sjobeck, and E. Englund, Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord, 2004. 18(2): p. 132-7.
Vermeer, S.E., W.T. Longstreth, Jr., and P.J. Koudstaal, Silent brain infarcts: a systematic review. Lancet Neurol, 2007. 6(7): p. 611-9.
de Leeuw, F.E., et al., Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry, 2001. 70(1): p. 9-14.
Launer, L.J., T.M. Hughes, and L.R. White, Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol, 2011. 70(5): p. 774-80.
Rincon, F. and C.B. Wright, Current pathophysiological concepts in cerebral small vessel disease. Front Aging Neurosci, 2014. 6: p. 24.
Fisher, C.M., Lacunes: Small, Deep Cerebral Infarcts. Neurology, 1965. 15: p. 774-84.
van der Flier, W.M., et al., Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke, 2005. 36(10): p. 2116-20.
Vermeer, S.E., et al., Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke, 2002. 33(1): p. 21-5.
DeCarli, C., et al., Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging, 2005. 26(4): p. 491-510.
Adachi, T., S. Kobayashi, and S. Yamaguchi, Frequency and pathogenesis of silent subcortical brain infarction in acute first-ever ischemic stroke. Intern Med, 2002. 41(2): p. 103-8.
Smith, E.E., et al., Cerebral microinfarcts: the invisible lesions. Lancet Neurol, 2012. 11(3): p. 272-82.
Vermeer, S.E., et al., Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med, 2003. 348(13): p. 1215-22.
Kobayashi, S., et al., Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke, 1997. 28(10): p. 1932-9.
Garde, E., et al., Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study. Lancet, 2000. 356(9230): p. 628-34.
Ylikoski, A., et al., White matter hyperintensities on MRI in the neurologically nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke, 1995. 26(7): p. 1171-7.
Kaffashian, S., et al., Differential Effect of White-Matter Lesions and Covert Brain Infarcts on the Risk of Ischemic Stroke and Intracerebral Hemorrhage. Stroke, 2016. 47(7): p. 1923-5.
Bernick, C., et al., Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology, 2001. 57(7): p. 1222-9.
Braffman, B.H., et al., Brain MR: pathologic correlation with gross and histopathology. 1. Lacunar infarction and Virchow-Robin spaces. AJR Am J Roentgenol, 1988. 151(3): p. 551-8.
Bokura, H., S. Kobayashi, and S. Yamaguchi, Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. J Neurol, 1998. 245(2): p. 116-22.
Jungreis, C.A., et al., Normal perivascular spaces mimicking lacunar infarction: MR imaging. Radiology, 1988. 169(1): p. 101-4.
Rouhl, R.P., et al., Virchow-Robin spaces relate to cerebral small vessel disease severity. J Neurol, 2008. 255(5): p. 692-6.
Weller, R.O., et al., White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol, 2015. 25(1): p. 63-78.
Cordonnier, C., R. Al-Shahi Salman, and J. Wardlaw, Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain, 2007. 130(Pt 8): p. 1988-2003.
Viswanathan, A. and S.M. Greenberg, Cerebral amyloid angiopathy in the elderly. Ann Neurol, 2011. 70(6): p. 871-80.
Greenberg, S.M., et al., Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke, 1996. 27(8): p. 1333-7.
Charidimou, A., et al., Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke, 2013. 44(4): p. 995-1001.
Charidimou, A. and D.J. Werring, Cerebral microbleeds and cognition in cerebrovascular disease: an update. J Neurol Sci, 2012. 322(1-2): p. 50-5.
Akoudad, S., et al., Cerebral microbleeds and the risk of mortality in the general population. Eur J Epidemiol, 2013. 28(10): p. 815-21.
Gregoire, S.M., et al., Cerebral microbleeds and long-term cognitive outcome: longitudinal cohort study of stroke clinic patients. Cerebrovasc Dis, 2012. 33(5): p. 430-5.
Charidimou, A., et al., Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology, 2013. 81(19): p. 1666-73.
Charidimou, A., et al., Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain, 2015. 138(Pt 8): p. 2126-39.
Fisher, C.M., Lacunar strokes and infarcts: a review. Neurology, 1982. 32(8): p. 871-6.
Kase, C.S., et al., Lobar intracerebral hematomas: clinical and CT analysis of 22 cases. Neurology, 1982. 32(10): p. 1146-50.
Norrving, B., Long-term prognosis after lacunar infarction. Lancet Neurol, 2003. 2(4): p. 238-45.
Miyao, S., et al., Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke, 1992. 23(10): p. 1434-8.
Ballard, C., et al., Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin, 2008. 24(9): p. 2561-74.
Das, R.R., et al., Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke, 2008. 39(11): p. 2929-35.
Inzitari, D., et al., Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ, 2009. 339: p. b2477.
Heron, M., Deaths: Leading Causes for 2014, 2016, National Vital Statistics Reports.
Poels, M.M., et al., Assessment of cerebral small vessel disease predicts individual stroke risk. J Neurol Neurosurg Psychiatry, 2012. 83(12): p. 1174-9.
Staals, J., et al., Total MRI load of cerebral small vessel disease and cognitive ability in older people. Neurobiol Aging, 2015. 36(10): p. 2806-11.
Charidimou, A., et al., Total Magnetic Resonance Imaging Burden of Small Vessel Disease in Cerebral Amyloid Angiopathy: An Imaging-Pathologic Study of Concept Validation. JAMA Neurol, 2016. 73(8): p. 994-1001.
Cunningham, C. and E. Hennessy, Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther, 2015. 7(1): p. 33.
Berlit, P., et al., [Cerebral amyloid angiopathy and dementia]. Nervenarzt, 2015. 86(10): p. 1248-54.
Abbott, N.J., Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol, 2000. 20(2): p. 131-47.
Becker, K.J. and M. Buckwalter, Stroke, Inflammation and the Immune Response: Dawn of a New Era. Neurotherapeutics, 2016.
Alexander, J.S. and J.W. Elrod, Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat, 2002. 200(6): p. 561-74.
Turner, R.J. and F.R. Sharp, Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Front Cell Neurosci, 2016. 10: p. 56.
Meraz-Rios, M.A., et al., Inflammatory process in Alzheimer's Disease. Front Integr Neurosci, 2013. 7: p. 59.
Auriel, E., et al., Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation. JAMA Neurol, 2016. 73(2): p. 197-202.
Shoamanesh, A., et al., Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology, 2015. 84(8): p. 825-32.
Seymour, H.E., et al., Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol, 2001. 51(3): p. 201-8.
Emsley, H.C. and P.J. Tyrrell, Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab, 2002. 22(12): p. 1399-419.
Ihara, M. and Y. Yamamoto, Emerging Evidence for Pathogenesis of Sporadic Cerebral Small Vessel Disease. Stroke, 2016. 47(2): p. 554-60.
Lourbopoulos, A., A. Erturk, and F. Hellal, Microglia in action: how aging and injury can change the brain's guardians. Front Cell Neurosci, 2015. 9: p. 54.
Ghosh, A., Brain APCs including microglia are only differential and positional polymorphs. Ann Neurosci, 2010. 17(4): p. 191-9.
Venneti, S., C.A. Wiley, and J. Kofler, Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol, 2009. 4(2): p. 227-43.
Shoamanesh, A., et al., Circulating biomarkers and incident ischemic stroke in the Framingham Offspring Study. Neurology, 2016. 87(12): p. 1206-11.
Friedland, R.P., Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis, 2015. 45(2): p. 349-62.
Fernandes, C.P., et al., Molecular analysis of oral bacteria in dental biofilm and atherosclerotic plaques of patients with vascular disease. Int J Cardiol, 2014. 174(3): p. 710-2.
Miyatani, F., et al., Relationship between Cnm-positive Streptococcus mutans and cerebral microbleeds in humans. Oral Dis, 2015. 21(7): p. 886-93.
Bath, P.M. and J.M. Wardlaw, Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke, 2015. 10(4): p. 469-78.
Odden, M.C., et al., Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension, 2016. 67(1): p. 63-9.
Investigators, S.P.S., et al., Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med, 2012. 367(9): p. 817-25.
Dufouil, C., et al., Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation, 2005. 112(11): p. 1644-50.
Gorter, J.W., Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology, 1999. 53(6): p. 1319-27.
Palumbo, V., et al., Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology, 2007. 68(13): p. 1020-4.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med, 1995. 333(24): p. 1581-7.
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet, 1997. 349(9066): p. 1641-9.
Romero, J.R., et al., Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke, 2014. 45(5): p. 1492-4.
Streifler, J.Y., et al., Prognostic importance of leukoaraiosis in patients with symptomatic internal carotid artery stenosis. Stroke, 2002. 33(6): p. 1651-5.
Wilcock, G., et al., A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol, 2002. 17(6): p. 297-305.
Auchus, A.P., et al., Galantamine treatment of vascular dementia: a randomized trial. Neurology, 2007. 69(5): p. 448-58.
Dichgans, M., et al., Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol, 2008. 7(4): p. 310-8.
Pieters, B., et al., Periventricular white matter lucencies relate to low vitamin B12 levels in patients with small vessel stroke. Stroke, 2009. 40(5): p. 1623-6.
Group, V.T.S., The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis, 2002. 13(2): p. 120-6.
Marti-Carvajal, A.J., et al., Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 2013(1): p. CD006612.
DOI: http://dx.doi.org/10.18103/imr.v2i11.265
Refbacks
- There are currently no refbacks.